Journal ArticleDOI
Vortioxetine (Lu AA21004) in generalized anxiety disorder: Results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial
Reads0
Chats0
TLDR
Vortioxetine was safe and effective in treating adults with GAD in this multinational population, and active treatment resulted in a significantly higher rate of remission.About:
This article is published in European Neuropsychopharmacology.The article was published on 2012-12-01. It has received 60 citations till now. The article focuses on the topics: Vortioxetine & Placebo.read more
Citations
More filters
Journal ArticleDOI
Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders
Martin A Katzman,Pierre Bleau,Pierre Blier,Pratap Chokka,Kevin Kjernisted,Michael Van Ameringen +5 more
TL;DR: These guidelines were developed by Canadian experts in anxiety and related disorders through a consensus process based on global impression of efficacy, effectiveness, and side effects, using a modified version of the periodic health examination guidelines.
Journal ArticleDOI
Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder.
TL;DR: Vortioxetine was efficacious and well tolerated in the treatment of patients with major depressive disorder; common adverse events were nausea, headache, diarrhea, dry mouth and dizziness.
Journal ArticleDOI
Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
TL;DR: The efficacy and safety of levomilnacipran (extended‐release capsules) for the treatment of major depressive disorder (MDD) are described.
Journal ArticleDOI
The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies
David S. Baldwin,David S. Baldwin,Lambros Chrones,Ioana Florea,Rebecca Z. Nielsen,George G. Nomikos,William Palo,Elin Heldbo Reines +7 more
TL;DR: Vortioxetine appears safe and generally well tolerated in the treatment of major depressive disorder and showed no clinically relevant effect on ECG parameters, including the QTcF interval.
Journal ArticleDOI
Emerging drugs for the treatment of anxiety.
TL;DR: This review will provide a critical summary of current pharmacological approaches to the treatment of anxiety and will examine the pharmacotherapeutic pipeline for treatments in development.
References
More filters
Journal ArticleDOI
The Hospital Anxiety and Depression Scale.
A. S. Zigmond,R. P. Snaith +1 more
TL;DR: It is suggested that the introduction of the scales into general hospital practice would facilitate the large task of detection and management of emotional disorder in patients under investigation and treatment in medical and surgical departments.
Journal ArticleDOI
The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.
John E. Ware,Cathy D. Sherbourne +1 more
TL;DR: A 36-item short-form survey designed for use in clinical practice and research, health policy evaluations, and general population surveys to survey health status in the Medical Outcomes Study is constructed.
Journal Article
The Mini-International Neuropsychiatric Interview (M.I.N.I.) : The development and validation of a Structured Diagnostic Psychiatric Interview for DSM-IV and ICD-10
David V. Sheehan,Yves Lecrubier,Kathy Harnett Sheehan,P. Amorim,J. Janavs,Emmanuelle Weiller,T. Hergueta,Ross A. Baker,Dunbar Geoffrey Charles +8 more
TL;DR: The Mini-International Neuropsychiatric Interview is designed to meet the need for a short but accurate structured psychiatric interview for multicenter clinical trials and epidemiology studies and to be used as a first step in outcome tracking in nonresearch clinical settings.
Journal ArticleDOI
A new depression scale designed to be sensitive to change.
Stuart Montgomery,Marie Åsberg +1 more
TL;DR: The construction of a depression rating scale designed to be particularly sensitive to treatment effects is described, and its capacity to differentiate between responders and non-responders to antidepressant treatment was better than the HRS, indicating greater sensitivity to change.
Journal ArticleDOI
Prevalence, Severity, and Comorbidity of 12-Month DSM-IV Disorders in the National Comorbidity Survey Replication
TL;DR: Although mental disorders are widespread, serious cases are concentrated among a relatively small proportion of cases with high comorbidity, as shown in the recently completed US National Comorbidities Survey Replication.